– Strong execution delivered second quarter 2023 total revenues of $957 million –
– Commercial excellence drove continued adoption of low-sodium Xywav^®; net product sales increased 39% year-over-year –
– Continued growth of Epidiolex^®; net product sales increased 15% 2Q23 year-over-year –
– Strong demand for Rylaze^® drove 39% increase in net product sales year-over-year –
– Oncology portfolio expected to reach ~$1 billion in net product sales this year –
– Zanidatamab leads a diversified pipeline with near-term catalysts positioned to deliver as many as four late-stage data readouts by the end of 2024 –